Cargando…
Management of breast cancer patients during the peak of the COVID 19 pandemic
Autores principales: | Montagna, E., Bellerba, F., Sangalli, C., Gandini, S., Cancello, G., Aliaga, P. Trillo, Galimberti, V., Leonardi, M.C., Iorfida, M., Munzone, E., Mazza, M., Dellapasqua, S., Mastrilli, F., Orecchia, R., Malengo, D., Omodeo Salè, E., Viale, G., Rietjens, M., Colleoni, M., Veronesi, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143908/ https://www.ncbi.nlm.nih.gov/pubmed/34116901 http://dx.doi.org/10.1016/j.ejso.2021.05.037 |
Ejemplares similares
-
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
por: Munzone, E., et al.
Publicado: (2021) -
Pegylated Liposomal Doxorubicin (Caelyx(®)) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
por: Dellapasqua, Silvia, et al.
Publicado: (2021) -
Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020) -
Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines
por: Munzone, Elisabetta, et al.
Publicado: (2019) -
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)